19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
15:47 , Aug 30, 2018 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer...
20:41 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting GDF11 could help treat osteoporosis. In a mouse model of estrogen deficiency-induced bone loss, an anti-GDF11 mAb increased the number, thickness and volume of trabeculae in the distal femur...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Acceleron Pharma Inc preclinical data

In mice, twice-weekly 10 mg/kg subcutaneous ACE-2494 increased muscle mass from baseline to week 4 by 40.9% in the rectus femoris, 53.3% in the gastrocnemius and 86.9% in the pectoralis vs. vehicle-treated controls (p?0.01 for...